Recombinant MVA vaccines: dispelling the myths (Q38092468)

28 August 2017

title

Recombinant MVA vaccines: dispelling the myths (English)

1 reference

28 August 2017

author

Matthew G. Cottingham

object named as

Matthew G Cottingham

series ordinal

1

0 references

author name string

Miles W Carroll

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

39

1 reference

28 August 2017

page(s)

4247-4251

1 reference

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Poxvirus-vectored vaccines for rabies--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Viral vectors as vaccine platforms: deployment in sight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Marker rescue of the host range restriction defects of modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

T-cell-inducing vaccines - what's the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Correlates of protection induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Genetic stability of recombinant MVA-BN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Dual neonate vaccine platform against HIV-1 and M. tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

An avian cell line designed for production of highly attenuated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

A chemically defined production process for highly attenuated poxviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Avian cell line - Technology for large scale vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Purification of cell culture-derived modified vaccinia ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Recombinant viral vectors: cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Modified vaccinia Ankara: potential as an alternative smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Authentication of the R06E fruit bat cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.03.021

1 reference

28 August 2017

1 reference